跳转至内容
Merck
CN

U103

U-69593

selective κ opioid receptor agonist, solid

别名:

(+)-(5α,7α,8β)-N-甲基-N-[7-(1-吡咯烷基)-1-氧杂螺[4,5]癸-8-基]苯乙酰胺, U69593

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C22H32N2O2
化学文摘社编号:
96744-75-1
分子量:
356.50
UNSPSC Code:
12352200
PubChem Substance ID:
24278769
NACRES:
NA.77
MDL number:
MFCD05664586

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

U-69593, solid

SMILES string

CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)Cc4ccccc4

InChI

1S/C22H32N2O2/c1-23(21(25)16-18-8-3-2-4-9-18)19-10-12-22(11-7-15-26-22)17-20(19)24-13-5-6-14-24/h2-4,8-9,19-20H,5-7,10-17H2,1H3/t19-,20-,22-/m0/s1

InChI key

PGZRDDYTKFZSFR-ONTIZHBOSA-N

form

solid

optical activity

[α]/D +7.8°, c = 0.825 in methanol(lit.)

color

white

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 10 mg/mL, 0.1 M HCl: >40 mg/mL, ethanol: >40 mg/mL, 0.1 M NaOH: insoluble, H2O: insoluble

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... OPRD1(4985), OPRK1(4986), OPRM1(4988)
mouse ... Oprk1(18387)
rat ... Oprd1(24613), Oprk1(29335), Oprm1(25601)

相关类别

Biochem/physiol Actions

U-69593是一种选择性κ阿片受体激动剂。已知U-69593可通过使多巴胺的基础溢流正常化来抑制中肢多巴胺神经元中的可卡因敏化。

Features and Benefits

《受体分类和信号转导》手册的 阿片类药物受体页有该化合物的介绍。想要浏览手册的其他页面， 请单击此处。

Preparation Note

U-69593可溶于45% (w/v) 2-羟丙基-环糊精水溶液（10 mg/ml）、0.1 M HCl（>40 mg/ml）以及乙醇（>40 mg/ml）。然而，它不溶于0.1 M NaOH和水。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000382428
0000382428
0000102364
0000073185
0000030456

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Xu Zhang et al.
Behavioural brain research, 236(1), 8-15 (2012-09-04)
Within a biopsychosocial model of pain, pain is seen as a conscious experience modulated by mental, emotional and sensory mechanisms. Recently, using a rodent visceral pain assay that combines the colorectal distension (CRD) model with the conditioned place avoidance (CPA)
Lisa E Baker et al.
Psychopharmacology, 203(2), 203-211 (2009-01-21)
Research interests regarding the psychopharmacology of salvinorin A have been motivated by the recreational use and widespread media focus on the hallucinogenic plant, Salvia divinorum. Additionally, kappa opioid (KOP) receptor ligands may have therapeutic potential in the treatment of some
Miriam Stoeber et al.
eLife, 9 (2020-02-26)
G protein-coupled receptors (GPCRs) signal through allostery, and it is increasingly clear that chemically distinct agonists can produce different receptor-based effects. It has been proposed that agonists selectively promote receptors to recruit one cellular interacting partner over another, introducing allosteric
Reagan L Pennock et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 31(1), 281-288 (2011-01-07)
Hypothalamic proopiomelanocortin (POMC) neurons release the endogenous opioid beta-endorphin and POMC neuron activity is inhibited by opioids, leading to the proposal that beta-endorphin acts to provide feedback inhibition. However, both intrinsic properties and synaptic inputs contribute to the regulation of
S Stevens Negus et al.
Experimental and clinical psychopharmacology, 16(5), 386-399 (2008-10-08)
Micro opioid receptor agonists are clinically valuable as analgesics; however, their use is limited by high abuse liability. Kappa opioid agonists also produce antinociception, but they do not produce micro agonist-like abuse-related effects, suggesting that they may enhance the antinociceptive
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持